Meeting
2014 ASCO Annual Meeting
A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
Authors
Huichung Tina Ling
The Permanente Medical Group, Hayward, CA
Huichung Tina Ling , Franco Muggia , James L. Speyer , John Patrick Curtin , Stephanie V. Blank , Leslie R. Boyd , Bhavana Pothuri , Xiaochun Li , Judith D. Goldberg , Amy Tiersten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01091259
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 5564)
DOI
10.1200/jco.2014.32.15_suppl.5564
Abstract #
5564
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
First Author: Salvia Sanjay Jain
Poster
2014 ASCO Annual Meeting
Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR) ovarian carcinoma (OVCA).
First Author: Joseph N. Kerger
Poster
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
First Author: Gordon Taylor Moffat
Poster
2022 ASCO Annual Meeting
Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).
First Author: Sebastian Stintzing